<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02307305</url>
  </required_header>
  <id_info>
    <org_study_id>cymbaltaTKR</org_study_id>
    <nct_id>NCT02307305</nct_id>
  </id_info>
  <brief_title>Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?</brief_title>
  <official_title>Does Duloxetine Reduce Chronic Pain After Total Knee Arthroplasty?</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hanyang University Seoul Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hanyang University Seoul Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Range from 24% to 44%, with a prevalence of neuropathic-type pain from 6% to 20%-cause
      impairment in quality of life and functional capacity after total knee arthroplasty(TKA).
      Duloxetine (cymbalta) is a selective serotonin and nor-epinephrine reuptake inhibitor shown
      to be effective in treating chronic pain. Serotonin and norepinephrine in the brain and
      spinal cord are believed to both mediate core mood symptoms and help regulate the perception
      of pain. Its effects on depression and anxiety symptoms, as well as its effect on pain
      perception, may be due to increasing the activity of serotonin and norepinephrine in the
      central nervous system. Approved for the acute and maintenance treatment of major depressive
      disorder, the acute treatment of generalized anxiety disorder, the management of diabetic
      peripheral neuropathic pain and the management of fibromyalgia, all in adults (18+).

      Investigators will compare the neuropathic pain following TKA in duloxetine group (n=84) with
      those in non-duloxetine group (n=84). Investigators will classify the participants in to 2
      groups (duloxetine and non-duloxetine group) randomly, and primarily evaluate the degree of
      neuropathic pain using the S-LANSS pain scale (preoperatively and postoperatively 3 and 6
      months). All participants will receive postoperative pain control after TKA using the same
      pain control regimen except duloxetine.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Both groups of participants will receive pain control regimens as follows:

      Preemptive analgesia : celebrex celecoxib, Patient controlled analgesia (postoperation 28
      hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge
      medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)

      Drug generic names: celecoxib (celebrex), naproxen/esomeprazole (vimovo),
      acetaminophen/tramadol (ultracet ER), oxycodone/naloxone (targin)
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>August 2014</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">December 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>neuropathic pain(the self assessed-Leeds Assessment of Neuropathic Symptoms and Signs pain scale, S-LANSS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Numeric rating scale for pain (NRS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>American Knee Society knee and function score</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster University Arthritis Index (WOMAC)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geriatric depression scale-short form</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">168</enrollment>
  <condition>Neuropathic Pain</condition>
  <arm_group>
    <arm_group_label>Duloxetin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
Phase II (titration): POD#1~6 (30mg for another 6 days)
Phase III (maintenance): POD#7~13(60mg for 7 days)
Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)
plus routine pain control (celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>routine pain control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)
Other name of drugs: celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Duloxetine</intervention_name>
    <description>Phase I (preemptive): 2 hour before surgery (30mg for 1 day)
Phase II (titration): POD#1~6 (30mg for another 6 days)
Phase III (maintenance): POD#7~13(60mg for 7 days)
Phase IV (tapering-1): POD#14~20 (30mg for 7 days)
Phase V (tapering-2): POD#21~27 (30mg another every day for 7 days)</description>
    <arm_group_label>Duloxetin group</arm_group_label>
    <other_name>cymbalta</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>celecoxib, naproxen/esomeprazole, acetaminophen/tramadol, oxycodone/naloxone</intervention_name>
    <description>Preemptive analgesia : celebrex, Patient controlled analgesia (postop. 28 hours), During admission : celebrex BP or vimovo BP +ultracet ER BP, targin HS, Discharge medication: celebrex BP or vimovo BP, ultracet ER BP(PRN)</description>
    <arm_group_label>Duloxetin group</arm_group_label>
    <arm_group_label>routine pain control group</arm_group_label>
    <other_name>celebrex, vimovo, ultracet, targin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Osteoarthritis of knee requiring TKA

        Exclusion Criteria:

          -  Rheumatoid arthritis

          -  Other inflammatory arthritis

          -  Neuropsychiatric patients

          -  Hepatic insufficiency

          -  Renal insufficiency

          -  Patients older than 75

          -  Allergy or intolerance to study medications

          -  Patients with an ASA of IV (angina, congestive heart failure, dementia,
             cerebrovascular accident)

          -  Chronic gabapentin or pregabalin use (regular use for longer than 3 months)

          -  Chronic opioid use (taking opioids for longer than 3 months)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Choonghyeok Choi</last_name>
    <role>Study Chair</role>
    <affiliation>Hanyang University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jinkyu Lee</last_name>
    <phone>+82-10-9582-7004</phone>
    <email>gaia-silver@hanmail.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Changhoon Lee</last_name>
    <phone>+82-10-8635-6990</phone>
    <email>toyessay@hanmail.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Orthopaedic Surgery, Hanyang University, College of Medicine</name>
      <address>
        <city>Seoul</city>
        <zip>133-792</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinkyu Lee</last_name>
      <phone>+82-10-9582-7004</phone>
      <email>gaia-silver@hanmail.net</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2014</study_first_submitted>
  <study_first_submitted_qc>December 1, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2014</study_first_posted>
  <last_update_submitted>February 17, 2016</last_update_submitted>
  <last_update_submitted_qc>February 17, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 19, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hanyang University Seoul Hospital</investigator_affiliation>
    <investigator_full_name>JIN KYU LEE</investigator_full_name>
    <investigator_title>Assistant professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Neuralgia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acetaminophen</mesh_term>
    <mesh_term>Celecoxib</mesh_term>
    <mesh_term>Naproxen</mesh_term>
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Duloxetine Hydrochloride</mesh_term>
    <mesh_term>Tramadol</mesh_term>
    <mesh_term>Naloxone</mesh_term>
    <mesh_term>Esomeprazole</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

